195 related articles for article (PubMed ID: 6488171)
1. Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice.
Lichtenstein AK; Berek J; Kahle J; Zighelboim J
Cancer Res; 1984 Nov; 44(11):5118-23. PubMed ID: 6488171
[TBL] [Abstract][Full Text] [Related]
2. Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity.
Lichtenstein AK; Kahle J; Berek J; Zighelboim J
J Immunol; 1984 Jul; 133(1):519-26. PubMed ID: 6373934
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity.
Bast RC; Knapp RC; Mitchell AK; Thurston JG; Tucker RW; Schlossman SF
J Immunol; 1979 Nov; 123(5):1945-51. PubMed ID: 489967
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of combination sequential immunotherapies in a murine ovarian cancer model.
Berek JS; Lichtenstein AK; Knox RM; Jung TS; Rose TP; Cantrell JL; Zighelboim J
Cancer Res; 1985 Sep; 45(9):4215-8. PubMed ID: 4028011
[TBL] [Abstract][Full Text] [Related]
5. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.
Lichtenstein A; Berek J; Bast R; Spina C; Hacker N; Knapp RC; Zighelboim J
J Biol Response Mod; 1984 Aug; 3(4):371-8. PubMed ID: 6541243
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy with biochemically dissociated fractions of Propionibacterium acnes in a murine ovarian cancer model.
Berek JS; Cantrell JL; Lichtenstein AK; Hacker NF; Knox RM; Nieberg RK; Poth T; Elashoff RM; Lagasse LD; Zighelboim J
Cancer Res; 1984 May; 44(5):1871-5. PubMed ID: 6713388
[TBL] [Abstract][Full Text] [Related]
7. Rejection of murine ovarian cancer following treatment with regional immunotherapy: correlations with a neutrophil-mediated activation of cytostatic macrophages.
Lichtenstein A
Cell Immunol; 1985 Sep; 94(2):521-35. PubMed ID: 4028167
[TBL] [Abstract][Full Text] [Related]
8. The distribution and persistence in vivo of Corynebacterium parvum in relation to its antitumor activity.
Scott MT; Milas L
Cancer Res; 1977 Jun; 37(6):1673-9. PubMed ID: 870181
[TBL] [Abstract][Full Text] [Related]
9. Requirements for successful immunotherapy and chemoimmunotherapy of a murine model of ovarian cancer.
Vanhaelen CP; Fisher RI
Cancer Res; 1981 Mar; 41(3):980-3. PubMed ID: 7193085
[TBL] [Abstract][Full Text] [Related]
10. Comparative antitumor effects of Corynebacterium parvum, Bordetella pertussis, Bacillus Calmette-Guérin, and levamisole alone or in combination with cyclophosphamide in the CaD2 murine mammary adenocarcinoma system.
Purnell DM; Bartlett GL; Kreider JW; Biro TG; Kontra J
Cancer Res; 1979 Dec; 39(12):4838-42. PubMed ID: 498111
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of thermal response of normal and malignant tissues by Corynebacterium parvum.
Urano M; Yamashita T; Suit HD; Gerweck LE
Cancer Res; 1984 Jun; 44(6):2341-7. PubMed ID: 6722772
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.
Bast RC; Berek JS; Obrist R; Griffiths CT; Berkowitz RS; Hacker NF; Parker L; Lagasse LD; Knapp RC
Cancer Res; 1983 Mar; 43(3):1395-401. PubMed ID: 6825108
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of the potentiation of specific antitumor immunity by intratumor injection of Corynebacterium parvum.
Miyata H; Himeno K; Nomoto K
Cancer Res; 1983 Oct; 43(10):4670-5. PubMed ID: 6883325
[TBL] [Abstract][Full Text] [Related]
14. [Passive transfer of "Corynebacterium parvum" anti-tumour protection by stimulated peritoneal cells ].
Mazurek C; Stiffel C; Chalvet H; Biozzi G
Ann Immunol (Paris); 1981; 132D(1):43-54. PubMed ID: 6896973
[TBL] [Abstract][Full Text] [Related]
15. Induction of resistance to ectromelia virus infection by corynebacterium parvum in murine peritoneal macrophages.
Cohen DA; Bubel HC
J Reticuloendothel Soc; 1983 Jan; 33(1):35-46. PubMed ID: 6300395
[TBL] [Abstract][Full Text] [Related]
16. Effects of Corynebacterium parvum treatment and Toxoplasma gondii infection on macrophage-mediated cytostasis of tumour target cells.
Krahenbuhl JL; Lambert LH; Remington JS
Immunology; 1976 Dec; 31(6):837-46. PubMed ID: 992714
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect between neutrophils and Corynebacterium parvum in the process of macrophage activation.
Chapes SK; Haskill S
Cancer Res; 1984 Jan; 44(1):31-4. PubMed ID: 6228293
[TBL] [Abstract][Full Text] [Related]
18. [Effect of silica on the anti-tumour activity of "Corynebacterium parvum" (author's transl)].
Mazurek C; Stiffel C; Chalvet H; Biozzi G
Ann Immunol (Paris); 1979; 130(6):815-26. PubMed ID: 232975
[TBL] [Abstract][Full Text] [Related]
19. Immunologic control of a retrovirus-associated murine adenocarcinoma. VI. Augmentation of antibody-dependent killing following quantitative and qualitative changes in host peritoneal cells.
Matthews TJ; Weinhold KJ; Langlois AJ; Bolognesi DP
J Natl Cancer Inst; 1985 Oct; 75(4):703-8. PubMed ID: 3862902
[TBL] [Abstract][Full Text] [Related]
20. In vivo transfer of antitumor activity by peritoneal exudate cells from mice treated with C. parvum.
Peters LJ; McBride WH; Mason KA; Hunter N; Basíc I; Milas L
Dev Biol Stand; 1977 Apr 13-15; 38():297-300. PubMed ID: 608514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
